Cyteir Therapeutics, Inc.
NASDAQ: CYT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Markus F. Renschler
- Employees
- 46
- Headquarters
- Lexington, United States
- IPO year
- 2021
- Market cap
- $108.7M
- Website
- https://cyteir.com
Loading CYT…
Loading profile data…Frequently asked questions about CYT
What does Cyteir Therapeutics, Inc. (CYT) do?
Cyteir Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to innovating and bringing to market cutting-edge precision oncology medicines. Its flagship compound, CYT-0851, is an novel, orally administered small molecule drug candidate, designed for once-daily dosing. This therapy is currently undergoing Phase I/II clinical ev...
Where does CYT trade?
Cyteir Therapeutics, Inc. (CYT) trades on the NASDAQ Global Select.
What sector is CYT in?
Cyteir Therapeutics, Inc. (CYT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cyteir Therapeutics, Inc.?
Markus F. Renschler is the chief executive officer of Cyteir Therapeutics, Inc. (CYT).
Where is Cyteir Therapeutics, Inc. headquartered?
Cyteir Therapeutics, Inc. is headquartered in United States.
Does CYT pay a dividend?
Cyteir Therapeutics, Inc. (CYT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CYT go public?
Cyteir Therapeutics, Inc. (CYT) completed its initial public offering in 2021.